ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,000 | -28.1% | 3,716 | +39.4% | 0.00% | – |
| Q2 2023 | $57,000 | -10.9% | 2,665 | +68.7% | 0.00% | – |
| Q1 2023 | $64,000 | -59.0% | 1,580 | -52.9% | 0.00% | – |
| Q4 2022 | $156,000 | +333.3% | 3,357 | +376.2% | 0.00% | – |
| Q3 2022 | $36,000 | +33.3% | 705 | +22.2% | 0.00% | – |
| Q2 2022 | $27,000 | -77.3% | 577 | -65.4% | 0.00% | – |
| Q1 2022 | $119,000 | -56.6% | 1,668 | -54.4% | 0.00% | – |
| Q4 2021 | $274,000 | +98.6% | 3,656 | +51.1% | 0.00% | – |
| Q3 2021 | $138,000 | +122.6% | 2,420 | +71.8% | 0.00% | – |
| Q2 2021 | $62,000 | +1450.0% | 1,409 | +1367.7% | 0.00% | – |
| Q1 2021 | $4,000 | -98.1% | 96 | -98.1% | 0.00% | – |
| Q4 2020 | $212,000 | -16.9% | 5,024 | -9.9% | 0.00% | – |
| Q3 2020 | $255,000 | +9.0% | 5,576 | +19.5% | 0.00% | – |
| Q2 2020 | $234,000 | -8.2% | 4,668 | -5.8% | 0.00% | – |
| Q1 2020 | $255,000 | +4150.0% | 4,953 | +5283.7% | 0.00% | – |
| Q4 2019 | $6,000 | -14.3% | 92 | -28.1% | 0.00% | – |
| Q3 2019 | $7,000 | -70.8% | 128 | -55.9% | 0.00% | – |
| Q2 2019 | $24,000 | -14.3% | 290 | 0.0% | 0.00% | – |
| Q1 2019 | $28,000 | +33.3% | 290 | 0.0% | 0.00% | – |
| Q4 2018 | $21,000 | -27.6% | 290 | -15.7% | 0.00% | – |
| Q3 2018 | $29,000 | -90.3% | 344 | -86.6% | 0.00% | – |
| Q2 2018 | $298,000 | -11.8% | 2,574 | -38.4% | 0.00% | – |
| Q1 2018 | $338,000 | +41.4% | 4,180 | +2.8% | 0.00% | – |
| Q4 2017 | $239,000 | -20.6% | 4,065 | -36.8% | 0.00% | – |
| Q3 2017 | $301,000 | +34.4% | 6,433 | +3.2% | 0.00% | – |
| Q2 2017 | $224,000 | -2.2% | 6,231 | -16.0% | 0.00% | – |
| Q1 2017 | $229,000 | +502.6% | 7,420 | +554.3% | 0.00% | – |
| Q4 2016 | $38,000 | +245.5% | 1,134 | +173.9% | 0.00% | – |
| Q3 2016 | $11,000 | -97.3% | 414 | -97.7% | 0.00% | – |
| Q2 2016 | $402,000 | -45.3% | 18,245 | -27.1% | 0.00% | – |
| Q1 2016 | $735,000 | +14.8% | 25,019 | +29.2% | 0.00% | – |
| Q4 2015 | $640,000 | -0.9% | 19,360 | +8.4% | 0.00% | – |
| Q3 2015 | $646,000 | -17.0% | 17,864 | +3.3% | 0.00% | -100.0% |
| Q2 2015 | $778,000 | +89.8% | 17,301 | +29.1% | 0.00% | – |
| Q1 2015 | $410,000 | +13.3% | 13,406 | +88.6% | 0.00% | – |
| Q4 2014 | $362,000 | +3520.0% | 7,110 | +2710.3% | 0.00% | – |
| Q3 2014 | $10,000 | -9.1% | 253 | +1.2% | 0.00% | – |
| Q2 2014 | $11,000 | -45.0% | 250 | -50.0% | 0.00% | – |
| Q1 2014 | $20,000 | +5.3% | 500 | -28.1% | 0.00% | – |
| Q4 2013 | $19,000 | – | 695 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |